Table 1.
Data on drug provocation testing (DPT) with chemotherapy agents from the large cohort of patients of the RCUH (Ramon y Cajal University Hospital), Madrid, Spain
| Alvarez-Cuesta E, et al. Allergy. 2015 | Madrigal-Burgaleta R, et al. JACI: In Practice. 2019 | ||||||
|---|---|---|---|---|---|---|---|
| Results from all chemotherapy-reactive patients referred over three years (n = 156) | Results from all chemotherapy-reactive referred patients in seven years (n = 515) | ||||||
| DPT Result |
Taxanes n = 43 |
Platins n = 95 |
Other n = 18 |
DPT Result |
Taxanes n = 135 |
Platins n = 188 |
Other n = 97 |
| Negative DPT 58/156 (37%) |
17/43 (40%) | 31/95 (33%) | 10/18 (56%) | Negative DPT 229/515 (45%) |
70/135 (52%) | 43/188 (23%) | 69/97 (71%) |
| Positive DPT 33/156 (21%) |
9/43 (21%) | 20/95 (21%) | 4/18 (22%) | Positive DPT 112/515 (22%) |
32/135 (24%) | 50/188 (27%) | 17/97 (18%) |
| DPT not undergone 65/156 (42%) |
17/43 (40%) |
44/95 (46% |
4/18 (22%) |
DPT not undergone 174/515 (34%) |
33/135 (24%) |
95/188 (51%) |
11/97 (12%) |
|
Results only from the patients who underwent DPT with chemotherapy (n = 91) |
Results only from the patients undergoing DPT with chemotherapy (n = 341) |
||||||
|
DPT Results |
Taxanes n = 26 |
Platins n = 51 |
Other n = 14 |
DPT Result |
Taxanes n = 102 |
Platins n = 93 |
Other n = 86 |
| Negative DPT 58/91 (64%) |
17/26 (65%) | 31/51 (61%) | 10/14 (71%) | Negative DPT 229/341 (67%) |
70/102 (69%) | 43/93 (46%) | 69/86 (80%) |
| Positive DPT 33/91 (36%) |
9/26 (35%) |
20/51 (39% |
4/14 (29%) |
Positive DPT 112/341 (33%) |
32/102 (31%) |
50/93 (54%) |
17/86 (20%) |
|
Safety results from the patients with a positive DPT to chemotherapy |
Safety results from the patients with a positive DPT with chemotherapy (n = 112) |
||||||
|
Severity Brown classification |
Taxanes n = 9 |
Platins n = 20 |
Other n = 4 |
Severity Brown classification |
Taxanes n = 32 (%) |
Platins n = 50 (%) |
Other n = 17 (%) |
| Grade 1 16/33 (48%) |
5/9 (56%) | 10/20 (50%) | 1/4 (25%) | Grade 1 48/112 (43%) |
11/32 (34%) | 27/50 (54%) | 5/17 (29%) |
| Grade 2 13/33 (39%) |
2/9 (22%) | 9/20 (45%) | 2/4 (50%) | Grade 2 47/112 (42%) |
14/32 (44%) | 16/50 (32%) | 10/17 (59%) |
| Grade 3 4/33 (12%) |
2/9 (22%) |
1/20 (5%) |
1/4 (25%) |
Grade 3 17/112 (15%) |
7/32 (22%) |
7/50 (14%) |
2/17 (12%) |
| Alvarez-Cuesta E, et al. Allergy. 2015 | Madrigal-Burgaleta R, et al. JACI: In Practice. 2019 | ||||||
n, number of patients; DPT, drug provocation test; DHR, drug hypersensitivity reaction.
This table has been modified from the data in the studies by Alvarez-Cuesta et al and Madrigal-Burgaleta et al to show only drug provocation test results from chemotherapy-reactive patients.